Fact-checked by Grok 2 weeks ago

Neonatal tetanus

Neonatal tetanus is an acute, toxigenic disease in infants under 28 days of age, caused by the released from germinating spores of the bacterium , which typically infect the umbilical stump following unhygienic cutting or dressing of the cord during . The condition arises in newborns lacking protective maternal antibodies, often in environments with poor sanitation and traditional practices such as applying unsterile substances to the stump, leading to spore germination in the environment. Symptoms usually emerge between 3 and 28 days post-birth, averaging 7 days, beginning with the inability to suck or cry normally, progressing to (), generalized muscle rigidity, and reflex spasms triggered by stimuli, which can cause and death. Without prompt administration, , and supportive care, the case-fatality rate approaches 100%, though survival improves with intensive intervention. Globally, neonatal tetanus has declined sharply due to targeted campaigns, with WHO estimating 24,000 deaths in 2021—a 88% reduction from 2000 levels—primarily burdening low-income regions where maternal tetanus coverage remains suboptimal and clean delivery kits are scarce. Prevention hinges on vaccinating women of childbearing age with at least two doses of tetanus before or during to confer , alongside promoting aseptic delivery and cord care practices that interrupt the causal chain from environmental contamination to toxin-mediated neuromuscular blockade.

Etiology and Pathogenesis

Causative Organism

Clostridium tetani is an obligate anaerobic, gram-positive, spore-forming, rod-shaped bacterium measuring approximately 0.3 to 0.5 μm in width and 2 to 2.5 μm in length, with peritrichous flagella conferring motility in its vegetative form. This organism is ubiquitous in the global environment, particularly in soil rich in , as well as in animal intestines and feces from species such as horses, , sheep, , and , facilitating widespread spore dissemination. Under anaerobic conditions, C. tetani produces , a 150-kDa zinc-dependent metalloprotease released during sporulation, which cleaves synaptobrevin (VAMP-2) in inhibitory presynaptic terminals, thereby blocking the release of inhibitory neurotransmitters such as and gamma-aminobutyric acid (). This molecular disruption prevents effective inhibition of motor neurons, culminating in unopposed excitatory signaling and spastic . ranks among the most potent natural toxins, with an estimated minimum human of 2.5 nanograms per kilogram of body weight. The endospores of C. tetani demonstrate exceptional , surviving extremes of (including brief ), , chemical disinfectants, , and oxygen exposure, which underscores their persistence in contaminated, unhygienic settings independent of host immunity. This durability arises from the spore's dehydrated core, protective coat layers, and dipicolinic acid content, enabling long-term environmental viability and potential for upon entry into niches like wounds.

Transmission in Neonates

Neonatal tetanus transmission occurs via contamination of the stump with spores at birth, primarily through the use of non-sterile cutting instruments or the application of contaminated materials to the stump during traditional delivery practices. In many cases, this involves home births where traditional birth attendants employ unsterilized tools, or apply substances such as animal dung, adulterated with , herbal concoctions, or other unhygienic pastes believed to promote healing or ward off . These practices introduce environmental spores, ubiquitous in , , and fecal matter, directly into the neonate's site. The vulnerability is exacerbated in of unvaccinated or inadequately immunized mothers, who fail to receive via transplacental transfer, leaving the newborn susceptible to from even minor . Empirical data link this transmission pathway predominantly to low-resource environments with suboptimal , unclean delivery surfaces, and limited hygienic protocols, where such cases account for nearly all reported neonatal incidents. Once introduced, spores germinate within the , devitalized of the umbilical stump, initiating after an incubation period ranging from 3 to 21 days, with a typical average of 7 days. Shorter incubation correlates with higher spore loads or proximity to neural , underscoring the causal role of initial wound inoculation in disease onset.

Pathophysiological Effects

Tetanospasmin, the primary responsible for manifestations, undergoes retrograde axonal transport from peripheral nerve endings to the following uptake at neuromuscular junctions or terminals. Once internalized by inhibitory in the and , the toxin's light chain functions as a zinc-endopeptidase that selectively cleaves synaptobrevin (vesicle-associated 2, or VAMP-2), a critical SNARE complex protein required for . This enzymatic action irreversibly disrupts the docking and fusion of vesicles with the presynaptic membrane, thereby inhibiting vesicular release. The cleavage of synaptobrevin specifically impairs the of inhibitory neurotransmitters g and gamma-aminobutyric acid () from presynaptic terminals of Renshaw cells and other inhibitory . Without these neurotransmitters, postsynaptic alpha motor neurons and their antagonists experience unopposed excitatory input from upper motor pathways, leading to hyperexcitability, reduced , and tetanic contractions due to persistent . Experimental models, including assays in , confirm accumulation in inhibitory neurons, correlating with the observed and supporting the toxin's central site of action over peripheral neuromuscular blockade. In neonatal tetanus, the core molecular mirrors that of generalized in adults, but is amplified by the absence of maternal anti-tetanus antibodies, which normally neutralize circulating before CNS entry, coupled with neonatal physiological immaturity such as underdeveloped glycinergic inhibition in spinal circuits and limited autonomic stability. This results in more rapid progression to severe , as neonates possess fewer compensatory neural reserves and exhibit heightened sensitivity to doses that might be sublethal in older individuals. findings in fatal cases reveal toxin-mediated neuronal degeneration predominantly in the anterior horn cells of the and nuclei, underscoring the central accumulation driving systemic effects.

Clinical Features

Onset and Progression

Neonatal tetanus typically has an of 3 to 14 days after birth, with symptoms most commonly appearing around day 7. Initial manifestations are often subtle, including poor sucking or feeding difficulties, , and excessive crying, reflecting early neuromuscular involvement from tetanospasmin toxin binding to inhibitory neurons. These signs arise as the toxin ascends via peripheral nerves to the , disrupting and GABA-mediated inhibition. Progression accelerates within hours to days of initial symptoms, beginning with () due to rigidity, followed by generalized muscle stiffness and opisthotonos—severe arching of the back from neck and abdominal rigidity. Painful, stimulus-triggered spasms ensue, involving the , , and respiratory muscles, leading to apneic episodes and as a primary terminal event. In neonatal cases, this escalation is notably rapid compared to adult , often culminating in autonomic instability and multiorgan compromise without intervention. Untreated, the condition carries a approaching 100%, predominantly from asphyxiation or cardiovascular collapse.

Primary Symptoms

The primary symptoms of neonatal tetanus arise from the neurotoxic effects of , leading to sustained muscle rigidity and episodic spasms. Affected neonates typically exhibit an inability to suckle or breastfeed, often presenting as the initial sign due to () and impaired . This is accompanied by in the jaw and neck muscles, progressing to generalized that restricts movement. Characteristic facial grimacing, known as , results from spasms of the facial muscles, giving a fixed, sardonic expression. Reflex spasms are triggered by minimal stimuli such as touch or noise, lasting from seconds to several minutes each and recurring every few minutes in early stages. These spasms involve opisthotonos, an arched rigidity of the back and neck. Autonomic dysfunction manifests as from , with heart rates exceeding 180 beats per minute, and fever often surpassing 38°C (100.4°F). and restlessness are common, reflecting involvement.

Associated Complications

constitutes the leading cause of death in neonatal tetanus, primarily arising from , spasm-induced obstruction of the airway, or fatigue of the and , which impairs and leads to and . Violent generalized spasms further exacerbate this by causing rib fractures or vertebral injuries, with fractures also reported due to the intensity of contractions. Nosocomial infections, including and , frequently complicate the course, particularly in resource-limited settings where prolonged or poor sterile techniques heighten vulnerability. Among survivors, long-term sequelae are documented, encompassing motor and sensory dysfunctions such as , cognitive-developmental delays, and , with one Nigerian series indicating these impairments in approximately 20% of cases. Neurodevelopmental outcomes vary by study; while some intensive care cohorts in showed no significant deficits compared to controls, others highlight persistent risks from hypoxic episodes or toxin-mediated neuronal damage. In resource-poor environments, untreated or inadequately managed neonatal tetanus carries a approaching 100%, with survival below 10-20% even under hospital care lacking full intensive support, as evidenced by 2024 case series from referral hospitals in . These outcomes underscore the causal progression from unchecked spasms to multi-organ failure, distinct from initial rigidity and .

Diagnosis

Clinical Assessment

The clinical assessment of neonatal tetanus relies on a detailed maternal and perinatal history, emphasizing risk factors such as delivery in unhygienic conditions—including the use of non-sterile instruments to cut the umbilical cord or application of contaminated substances like animal dung or soil to the stump—and absence of maternal immunization with tetanus toxoid vaccine during pregnancy. These practices facilitate Clostridium tetani spore entry via the umbilical wound, a causal pathway distinct from other neonatal infections due to the toxin-mediated mechanism rather than direct bacterial invasion. Bedside evaluation focuses on the characteristic progression: normal ability to suck and cry within the first two days of life, followed by refusal to feed, (), and episodic generalized muscle s or rigidity, typically without fever or signs of systemic at onset. The World Health Organization's surveillance criteria for a confirmed case stipulate a neonate under 28 days old exhibiting this sequence, with spasms triggered by stimuli, and exclusion of alternative etiologies through clinical judgment rather than assuming concurrent conditions like without corroborating features such as or positive cultures. This triad—recent unhygienic birth history, spasm predominance without initial fever, and lack of evident alternative source—guides presumptive , as the toxin's neuromuscular blockade produces rigidity and spasms via inhibition of inhibitory neurotransmitters, a not replicated by bacterial alone. Differentiation from mimics poses empirical challenges, as early irritability, , or poor feeding may resemble or , but progression to stimulus-evoked spasms and (grimacing from facial rigidity) without respiratory distress from or argues against those, requiring serial observation to confirm the -specific pattern over nonspecific neonatal distress. In resource-limited settings where remains prevalent, over-diagnosis as occurs due to overlapping feeding difficulties, yet first-principles exclusion prioritizes the absence of fever, focal infection signs, or rapid response to antibiotics, which fail in tetanus owing to its non-antibiotic-responsive effects.

Confirmatory Tests

The diagnosis of neonatal tetanus is predominantly clinical, with laboratory and ancillary tests serving only supportive roles due to the absence of routine assays capable of directly detecting unbound tetanus toxin in vivo. Cultures from the umbilical stump or any suspected wound site may attempt to isolate Clostridium tetani, the causative anaerobe, but yield is low—often negative even in confirmed cases—owing to the bacterium's sporadic presence, rapid spore germination, and frequent prior antibiotic exposure disrupting vegetative growth. Serologic evaluation of maternal or neonatal tetanus antitoxin immunoglobulin G levels can reveal protective thresholds (typically ≥0.1 IU/mL), which are absent or suboptimal in unvaccinated mothers, heightening neonatal risk; however, detectable levels do not exclude disease, as circulating toxin binds irreversibly to neural tissues before systemic dissemination. Electromyography (EMG) provides electrophysiological corroboration by demonstrating characteristic continuous motor unit firing, shortened or absent silent intervals post-stimulation, and repetitive discharges, distinguishing tetanus from mimics like or in resource-equipped settings. This modality's utility is ancillary, aiding ambiguous presentations but not supplanting history and exam findings of rigidity and spasms originating from the umbilicus. Imaging modalities such as computed tomography or magnetic resonance are generally avoided unless evaluating complications like or autonomic instability, as they offer no diagnostic specificity for the toxin-mediated neuromuscular blockade. U.S. Centers for Disease Control and Prevention (CDC) surveillance protocols, updated through 2025, underscore that no laboratory metric—whether microbiologic, serologic, or electrodiagnostic—can confirm or refute , prioritizing clinical syndromic criteria to facilitate rapid intervention amid the disease's near-100% case-fatality without neutralization. guidelines similarly affirm clinical primacy, noting laboratory pursuits' marginal value in low-resource neonatal contexts where empirical management prevails.

Treatment

Initial Stabilization

The initial stabilization of neonatal tetanus prioritizes airway protection and spasm suppression to prevent , which accounts for most deaths in untreated cases. Neonates exhibiting or require prompt assessment for endotracheal and , as uncontrolled spasms can lead to or . Supportive measures include the in a quiet, darkened room to reduce sensory stimuli that exacerbate rigidity and spasms. with intravenous benzodiazepines, such as at an initial bolus of 0.1-0.2 mg/kg followed by continuous infusion of 0.4-1.2 mg/kg/day titrated to control spasms without excessive respiratory depression, forms the cornerstone of early muscle relaxation. Wound management targets the umbilical stump, the primary portal of entry for spores in neonates. Thorough irrigation with saline, excision of necrotic tissue, and under eliminate residual spores and devitalized material that perpetuate toxin production. This , when performed early in resource-equipped facilities, correlates with reduced bacterial burden and improved outcomes compared to delayed care. Autonomic nervous system instability, including , , or arrhythmias, necessitates continuous hemodynamic monitoring via arterial lines or echocardiography-adapted non-invasive methods suitable for neonates. Sympatholytic agents like short-acting beta-blockers (e.g., 0.01-0.1 mg/kg IV) address episodic , while avoiding agents that risk precipitous . In select cases, infusion has stabilized autonomic dysfunction when standard therapies prove insufficient. These measures, distinct from administration, aim to bridge to definitive therapy while mitigating immediate life-threatening derangements.

Specific Therapies

The primary specific therapy for neonatal tetanus involves administration of human tetanus immune globulin (HTIG) to neutralize unbound toxin produced by . A single dose of 500 HTIG is recommended intramuscularly, as this provides by binding circulating toxin without affecting toxin already internalized in neural tissues. Higher doses up to 3000-6000 , typically used in adults, have not demonstrated superior outcomes in neonates and may increase risks such as hypersensitivity reactions. HTIG must be given promptly upon suspicion of tetanus, as empirical data indicate it reduces free toxin levels but cannot reverse established neurological binding or symptoms. Antimicrobial therapy targets eradication of C. tetani from the infection site, primarily the umbilical stump, to halt further production; however, antibiotics have no effect on pre-released , underscoring their adjunctive role post-antitoxin administration. is preferred over penicillin G due to comparable or superior efficacy against C. tetani and avoidance of penicillin's potential GABA antagonism, which could exacerbate spasms. In neonates, intravenous is dosed at 30 mg/kg/day divided every 6-8 hours for 7-10 days, with penicillin G (150,000-200,000 /kg/day IV divided every 4-6 hours) as an alternative if is unavailable or contraindicated. is generally unnecessary given consistent C. tetani susceptibility, though with agents like cephalosporins may be considered in polymicrobial infections. Wound management, including thorough cleaning and possible excision of the contaminated umbilical stump, complements and antibiotics by removing bacterial reservoirs, though feasibility in neonates is limited by anatomical constraints. No routine role exists for active during acute , as the neonate's immature precludes meaningful production amid ongoing effects.

Prognosis Factors

The prognosis of neonatal tetanus remains grave, with case-fatality rates historically exceeding 90% in untreated cases due to from spasms and autonomic instability. Shorter periods, typically defined as 7 days or less from birth to symptom onset, strongly correlate with poorer outcomes, reflecting greater burden and more rapid neurological involvement; studies report mortality rates of 71% for incubations of 6 days or fewer compared to 47% for longer periods. Access to intensive care profoundly influences survival, as mitigates the primary cause of death—laryngospasm and —with fatality dropping to 10-20% in facilities equipped for prolonged support, versus near-total mortality in resource-limited settings lacking such interventions. Delayed presentation to care, often exceeding 24-48 hours from symptom onset, exacerbates outcomes by allowing unchecked toxin progression and secondary complications like . (<2.5 kg) independently predicts higher mortality, likely due to immature physiological reserves against spasms and . Survival does not confer immunity, as the disease results from toxin effects rather than adaptive response to ; affected neonates require tetanus toxoid vaccination per standard schedules to prevent recurrence. Long-term data from the indicate persistent high lethality in endemic areas without maternal immunization, underscoring these factors' interplay in outcome determination.

Prevention

Vaccination Protocols

Prevention of neonatal tetanus relies primarily on maternal with -containing vaccines (TTCV), such as (TT), tetanus-diphtheria (Td), or tetanus-diphtheria-acellular pertussis (Tdap), which induces protective antibodies that cross the to provide to the newborn. This transplacental transfer confers protection against toxin during the vulnerable neonatal period, when the risk of infection from umbilical cord contamination is highest. The (WHO) recommends that women of reproductive age receive at least two lifetime doses of TTCV to eliminate maternal and neonatal tetanus (MNT), with integration into routine antenatal care to ensure timely administration. For pregnant women without prior tetanus history, the protocol involves administering two doses of TTCV during the current , spaced at least four weeks apart, with the first dose ideally early in and the second before delivery to maximize transfer. In cases of incomplete prior , a third dose may be required to complete the primary series, achieving optimal protection. For women previously immunized, a single of Tdap is advised during each , preferably between 27 and 36 weeks of , to reinforce maternal immunity and enhance neonatal levels. This approach avoids the need for neonatal , as maternal antibodies suffice to cover the critical early postnatal period before the infant's own begins. Empirical data demonstrate high efficacy of maternal TTCV , with two or more doses reducing neonatal tetanus mortality by 94-96%. WHO-supported campaigns integrating these protocols into antenatal services have contributed to MNT elimination in 47 countries by , with global neonatal tetanus cases declining 88% since 2000. Adherence to these guidelines, verified through and serological studies, underscores the causal role of sustained maternal titers in averting toxin-mediated in neonates.

Hygienic Delivery Practices

Hygienic delivery practices are essential for preventing spore contamination of the umbilical stump, the primary entry point for neonatal in unvaccinated newborns. These practices focus on sterility during cord severance and subsequent care to interrupt transmission, independent of maternal . Core elements include using a sterile instrument, such as a boiled or new blade, to cut the cord, performed by a birth attendant with washed in boiled water or solution. Application of contaminated substances like animal dung, ash, or to the stump—traditional practices in some regions—introduces spores from or , substantially elevating risk; studies in rural settings have linked such applications to higher neonatal tetanus incidence. Post-delivery cord care emphasizes keeping the stump clean and dry, avoiding dressings or substances that retain moisture or harbor . In low-resource environments, dry cord care—leaving the stump exposed to air without antiseptics—has proven effective for prevention when combined with initial sterility, outperforming unhygienic traditional methods and requiring no specialized supplies. Antiseptics like may offer marginal benefits in high- settings but are not superior to dry care for reducing omphalitis or risk in resource-limited areas where access is inconsistent. Employing skilled birth attendants, trained in these protocols, markedly lowers neonatal tetanus rates by ensuring adherence to sterile techniques during home or facility deliveries. Empirical data indicate that deliveries assisted by such attendants, often using clean birth kits containing sterile tools and gloves, are associated with significant reductions in tetanus cases, with population-level interventions showing up to 90% declines in incidence where coverage exceeds 80%. Home births without hygiene kits or trained support persist as high-risk scenarios, as non-sterile cutting and unhygienic handling directly facilitate spore germination in the anaerobic stump environment.

Broader Public Health Strategies

The World Health Organization's Maternal and Neonatal Tetanus Elimination Initiative, launched in 1999 and targeting 59 high-burden countries, employs large-scale vaccination campaigns with tetanus toxoid-containing vaccines for women of reproductive age, alongside capacity-building for health workers in safe delivery and cord care practices. These systemic efforts have validated elimination—defined as fewer than one neonatal tetanus case per 1,000 live births in every district—in 49 countries by December 2024. Reported neonatal tetanus cases worldwide declined 89% from 17,935 in 2000 to 1,995 in 2021, reflecting the initiative's impact through sustained drives and integration with routine programs like diphtheria-tetanus-pertussis (DTP) schedules to boost long-term coverage. Estimated deaths fell approximately 97% from 787,000 in 1988 to 25,000 in 2018, underscoring the causal efficacy of population-level in averting toxin-mediated mortality. Robust networks detect clusters and subpopulations at risk, enabling rapid outbreak investigations and targeted supplementary activities to prevent resurgence, while data inform across districts.

Neonatal tetanus remains a significant cause of mortality among newborns, with an estimated 25,000 deaths occurring globally in 2018, representing a highly where over 99% of cases can be averted through maternal immunization and hygienic practices. More recent modeling estimates indicate further reductions, with approximately 7,719 neonatal tetanus deaths in 2021, comprising about 0.3% of all-cause neonatal mortality worldwide. These deaths predominantly affect neonates in settings with limited access to tetanus toxoid-containing vaccines. Global incidence has shown substantial decline, with reported neonatal tetanus cases decreasing 89% from 17,935 in 2000 to 1,995 in 2021, paralleled by an 84% drop in estimated deaths from 46,898 in the same period. This progress builds on a broader trend from an estimated 787,000 neonatal deaths in 1988, reflecting the impact of intensified immunization campaigns under the WHO-led Maternal and Neonatal Tetanus Elimination initiative. Despite these gains, surveillance data suggest stagnation or slower reductions in certain high-burden areas, underscoring ongoing challenges in achieving elimination. In low-income countries, neonatal tetanus accounts for roughly 50% of all cases, highlighting its disproportionate burden relative to other forms in resource-constrained environments. Continued global efforts have validated elimination in 49 of 59 priority countries as of December 2024, yet persistent in the remaining areas sustains the overall disease load.

Risk Factors

The principal risk factor for neonatal tetanus is maternal lack of against , which prevents the transplacental transfer of protective antibodies to the newborn, leaving the infant susceptible to toxin following contamination. This environmental exposure, rather than any , determines infection, as the disease arises solely from spore germination in anaerobic wounds producing . Unhygienic delivery practices, including the use of non-sterile instruments to cut the or application of contaminated substances such as dung, ash, or to the stump, directly facilitate bacterial entry and , with cultural practices involving such applications markedly elevating odds of onset. births attended by untrained personnel or on unclean surfaces further compound this vulnerability by increasing contamination likelihood during the critical perinatal period. Low socioeconomic conditions correlate with these modifiable behaviors, such as inadequate access to sterile materials or , thereby linking not causally but through heightened exposure to spores in resourceless environments. Neonatal tetanus incidence remains highest among unvaccinated populations, with empirical confirming near-elimination in immunized cohorts due to these targeted determinants.

Regional Variations

Neonatal tetanus persists predominantly in low- and middle-income regions with limited healthcare infrastructure, particularly and , where these areas accounted for over 80% of global cases as of recent analyses. In , incidence rates remain elevated, with Eastern sub-Saharan Africa reporting the highest at 6.59 cases per 100,000 children under five in 2023 data. Countries such as , of Congo, and continue to report clusters, linked to inconsistent coverage and unhygienic delivery practices in rural districts. , including and , similarly sustains transmission, with neonatal cases tied to home births and gaps in maternal . In contrast, neonatal tetanus has been virtually eliminated in high-income regions like and the , where comprehensive vaccination programs and institutionalized deliveries have reduced incidence to negligible levels. By December 2024, 49 of 59 priority countries worldwide had achieved validated maternal and neonatal tetanus elimination status, primarily encompassing the , , and parts of , reflecting sustained investments. The remaining 10 non-validated countries—Afghanistan, , , , Democratic Republic of Congo, , , , , and —are concentrated in and , underscoring geographic clustering in under-resourced zones. Regional disparities correlate strongly with socioeconomic indicators, including female literacy rates and maternal healthcare access; studies indicate that mothers with levels exhibit 47% greater odds of tetanus toxoid uptake, facilitating protection for newborns. In areas with frequent antenatal care visits (4–7 times per ), coverage improves, reducing neonatal risk, as evidenced by WHO analyses of system failures in delivery and routine . Urban-rural divides exacerbate this, with rural populations in endemic zones facing 2–3 times higher incidence due to reliance on traditional birth attendants and limited sterile cord care. Conflict-affected areas, such as and surrounding populations, report sporadic 2024 cases amid disrupted services and , highlighting vulnerabilities in transient, underserved groups despite regional elimination efforts elsewhere in the . These patterns align with broader development gradients, where GDP per capita and health expenditure inversely predict persistence, independent of global trends.

History

Early Descriptions

Neonatal tetanus, a form of generalized affecting newborns, was first recognized in ancient medical texts through descriptions of symptoms such as , or "locked jaw," and muscle spasms in infants. , in the 5th century BCE, documented three varieties of tetanus in newborns, attributing the condition to exposure following , though without identifying a specific infectious cause. similarly noted convulsions and rigidity in affected infants, linking early observations to perinatal events. By the , clinicians increasingly associated neonatal tetanus with infections from unhygienic cutting or dressing practices, distinguishing it as a preventable perinatal condition. In isolated communities, such as the St Kilda archipelago in the , neonatal tetanus accounted for two-thirds of deaths over at least 150 years, often due to contamination from unsterile tools or substances applied to the cord stump. Similar patterns emerged on the Westman Islands off , where the disease posed a major hazard in the early 1800s, highlighting the role of traditional in transmission. The infectious etiology was experimentally confirmed in 1884 by Italian pathologists Antonio Carle and Giorgio Rattone, who induced in rabbits by injecting from a case, demonstrating bacterial transmission applicable to neonatal forms via wound contamination like the umbilical site. Prior to , neonatal tetanus caused substantial mortality, with estimates exceeding 500,000 annual global deaths in unvaccinated populations during the early , reflecting its persistence in regions lacking maternal or aseptic practices.

Vaccine Development and Milestones

The tetanus toxoid, an inactivated form of the Clostridium tetani toxin, was first developed in 1924 by French researcher P. Descombey, building on Gaston Ramon's earlier work with diphtheria toxoid and formalin inactivation techniques. This innovation enabled active immunization against tetanus by inducing antibody production without causing disease, marking a pivotal advancement in preventing toxin-mediated illnesses like neonatal tetanus, where maternal antibodies transferred via placenta protect newborns. By the late 1930s, adsorbed tetanus toxoid—enhanced for better immunogenicity through aluminum salts—became available, and in the 1940s, it was combined with diphtheria toxoid and whole-cell pertussis vaccine to form the DTP formulation, facilitating widespread childhood immunization. During , tetanus toxoid vaccination was extensively administered to military personnel, drastically reducing tetanus incidence from rates seen in , with U.S. Army cases dropping to 12 per million soldiers, primarily among the under-immunized. Post-war, in the late 1940s, tetanus toxoid-containing vaccines entered routine civilian programs in developed nations, correlating with sharp declines in tetanus morbidity; for instance, U.S. notifications fell from hundreds annually pre-vaccine to near elimination by the 1970s, attributable to high coverage rather than improved hygiene alone, as toxin production remains ubiquitous in . This causal link was reinforced by military data showing vaccination's direct protective effect independent of wound care advances. In response to 1988 estimates of 787,000 neonatal tetanus deaths globally—predominantly in unvaccinated mothers in low-resource settings—the World Health Organization's 1989 resolution urged elimination by 1995 through maternal tetanus campaigns. Though delayed beyond initial targets, trials of antenatal maternal vaccination demonstrated 88–100% reductions in neonatal cases in intervention areas, with placental antibody transfer providing until infants could be vaccinated. These efforts, emphasizing two properly spaced tetanus doses for previously unvaccinated women, causally drove a 96% global drop in neonatal tetanus deaths from 1988 levels by 2015, underscoring vaccination's primacy over ancillary measures in high-burden regions.

Eradication Challenges

Cultural and Behavioral Barriers

In certain rural communities in and , traditional postpartum rituals involve applying unsterile substances such as , () mixed with dung, , or herbal pastes to the newborn's stump, purportedly to facilitate drying, promote healing, or provide spiritual protection. These practices contaminate the wound with spores prevalent in animal feces and soil, while the organic materials create moist, anaerobic conditions ideal for spore and production. Case-control studies have identified such applications as a significant independent for neonatal tetanus, with contaminated alone associated with multiple outbreaks due to covert dung residues. Empirical data from endemic regions underscore the risks: deliveries involving traditional cord care without sterile implements or antiseptics correlate with rates far exceeding those in hygienic settings, as unsterile substances foster bacterial in the devitalized . For example, in cohort analyses, umbilical stump treatments with dung or similar materials have been linked to neonatal tetanus incidence rates orders of magnitude higher than clean cord care protocols, though exact multipliers vary by local prevalence of spores. These customs endure despite interventions, as communities often prioritize cultural continuity and perceived ancestral wisdom over biomedical evidence demonstrating inefficacy and harm. A related behavioral pattern is the preference for untrained traditional birth attendants (TBAs) in home deliveries, where resistance to adopting aseptic techniques—such as using boiled instruments or clean —stems from entrenched trust in informal networks over formal systems. TBAs frequently perform cord cuttings with blades or under unhygienic conditions, elevating ; population-attributable risk estimates attribute approximately 24% of neonatal tetanus cases to the absence of such . This reliance persists in areas valuing community-embedded practices, with ethnographic reports noting TBA programs yielding limited reductions in transmission due to incomplete adherence to standards.

Vaccine Hesitancy Issues

Vaccine hesitancy regarding maternal vaccination contributes to persistent neonatal tetanus cases by promoting unfounded fears that undermine uptake, despite robust evidence of the vaccine's safety and efficacy in preventing the disease. In 2014, rumors in alleged that tetanus toxoid vaccines contained (hCG) to induce or sterilization, propagated by elements within the ; independent testing by WHO and confirmed no such additives, debunking the claims as rooted in theories rather than . Similar sterility fears have recurred in other campaigns, but controlled studies, including antigen-specific assays, have repeatedly found no causal link between tetanus toxoid and reproductive harm. Religious and philosophic objections also drive hesitancy in select groups, where parents cite doctrinal concerns against , leading to unvaccinated infants at risk; for instance, U.S. data from 1995–1997 identified religious exemptions as a factor in neonatal occurrences among otherwise preventable cases. These objections persist despite theological endorsements from major institutions, such as the Catholic Church's support for tetanus campaigns when fetal cell lines are avoided. Empirical affirm the safety of tetanus-containing like Tdap or during , with large-scale studies showing no increased risks of chorioamnionitis, , or infant adverse outcomes beyond rare (incidence <1 per million doses). A 2025 qualitative study of Syrian pregnant refugees in Türkiye revealed hesitancy linked to of foreign ("") , fears of unknown side effects, and , even in contexts where high-compliance areas report zero neonatal tetanus; participants expressed doubts about long-term efficacy despite historical showing maternal reduces neonatal cases by over 90% in vaccinated cohorts. Such hesitancy causally perpetuates preventable deaths, as global neonatal tetanus cases—estimated at 1,995 in 2021—occur almost exclusively in regions with low maternal coverage (<80%), sustaining an attributable mortality burden where full could eliminate . Countering these issues requires targeted education privileging randomized trial data over anecdotal fears, as hesitancy correlates with underreporting of benefits like against Clostridium tetani spores.

Systemic and Logistical Hurdles

In high-burden countries, unreliable cold chains compromise the efficacy of tetanus toxoid (TT) vaccines, as the vaccine requires consistent refrigeration between 2–8°C during transport and storage, yet frequent power outages and inadequate equipment in remote facilities lead to potency loss. This infrastructural failure is exacerbated in rural areas, where poor road networks and limited vehicle access hinder vaccine delivery campaigns, resulting in uneven distribution and missed opportunities for maternal immunization. Conflict zones further disrupt logistics, as ongoing instability in regions like parts of Afghanistan and Somalia—among the 10 countries yet to achieve maternal and neonatal tetanus elimination as of June 2024—prevents consistent access to health outposts and interrupts scheduled vaccination drives. Underfunding diverts resources from -specific initiatives toward competing priorities such as infectious outbreaks, leaving WHO elimination goals unmet despite global neonatal tetanus cases dropping 89% from 2000 to 2021. Empirical gaps compound this, with suboptimal case reporting in under-resourced areas delaying outbreak detection and response; for instance, WHO-recommended active through site visits often falters due to personnel shortages, allowing hidden transmission chains to persist. In non-eliminated countries, tetanus toxoid-containing (TTCV) coverage for pregnant women averages lower than in achieved nations, reflecting these systemic shortfalls rather than isolated attitudinal factors.

References

  1. [1]
    Clinical Overview of Tetanus - CDC
    Jun 10, 2025 · Neonatal tetanus. Symptoms usually appear from 4 to 14 days after birth, averaging about 7 days. Cephalic tetanus. The incubation period is ...Key Points · Cause · Diagnosis
  2. [2]
    Tetanus (Clostridium tetani Infection) - StatPearls - NCBI Bookshelf
    Feb 26, 2024 · Tetanus is a life-threatening disorder characterized by painful muscular spasms, hypertonia, and autonomic nervous system dysfunction.Tetanus (clostridium Tetani... · Epidemiology · Treatment / Management
  3. [3]
    Chapter 21: Tetanus | Pink Book - CDC
    Apr 25, 2024 · Neonatal tetanus occurs in infants born without protective passive immunity because the mother is not immune. It usually occurs through ...Vaccination Schedule And Use · Use Of Tdap · Contraindications And...
  4. [4]
    Eliminating Maternal and Neonatal Tetanus and Promoting Clean ...
    Oct 29, 2019 · In neonatal tetanus, the umbilical stump acts as an entry point for the bacteria after unhygienic delivery and cord care practices (2). In ...
  5. [5]
    Clinical Features of Tetanus - CDC
    Jun 10, 2025 · Neonatal tetanus is a form of generalized tetanus. It occurs in newborns who lack the passive protection derived from maternal antibodies.Key Points · Clinical Presentations · Common Signs And Symptoms
  6. [6]
    Tetanus - World Health Organization (WHO)
    Jul 12, 2024 · The WHO definition of a confirmed neonatal tetanus case is an illness occurring in an infant who has the normal ability to suck and cry in the ...
  7. [7]
    Tetanus: Background, Pathophysiology, Etiology
    Feb 5, 2025 · Tetanus is characterized by an acute onset of hypertonia, painful muscular contractions (usually of the muscles of the jaw and neck), and generalized muscle ...
  8. [8]
    Maternal and Neonatal Tetanus Elimination (MNTE)
    WHO estimates that in 2021 (the latest year for which estimates are available), 24,000 newborns died from NT, 88% reduction from the situation in 2000 figure of ...
  9. [9]
    Chapter 16: Tetanus | Manual for the Surveillance of Vaccine ... - CDC
    Oct 22, 2024 · Tetanus is an acute, potentially fatal disease characterized by generalized rigidity and convulsive spasms of skeletal muscles.Background · Reporting And Case... · Enhancing SurveillanceMissing: symptoms | Show results with:symptoms
  10. [10]
    Tetanus toxoid immunization to reduce mortality from neonatal tetanus
    There were 71 neonatal tetanus deaths in the two highest quality studies with an overall evidence grade of moderate, hence more than the minimum of 50 events ...
  11. [11]
    Clostridium tetani - an overview | ScienceDirect Topics
    Clostridium tetani is a gram-positive, spore-forming, motile, anaerobic bacillus.61–65 Typically measuring 0.3 to 0.5 μm in width and 2 to 2.5 μm in length, the ...
  12. [12]
    Comparative pathogenomic analysis reveals a highly tetanus toxin ...
    Nov 27, 2023 · C. tetani is a Gram-positive, anaerobic, spore-forming bacterium that is widely distributed in the soil. It is resistant to heat, desiccation, ...
  13. [13]
    Clostridium tetani - an overview | ScienceDirect Topics
    Clostridium tetani is an anaerobic, Gram-positive, spore-forming rod. The spores are highly resilient, which explains their ubiquity, and can easily contaminate ...
  14. [14]
    Neonatal tetanus: risk communication and community engagement ...
    Neonatal tetanus occurs when nonsterile instruments are used to cut the umbilical cord or when contaminated material is used to cover the umbilical stump.
  15. [15]
    Neonatal tetanus associated with topical umbilical ghee - PubMed
    Neonatal tetanus associated with topical umbilical ghee: covert role of cow dung ... unhygienic handling practices would eventually result in microbial infection.Missing: home births herbal
  16. [16]
    Maternal and neonatal tetanus | UNICEF South Sudan
    Mar 8, 2018 · “She also said that the baby's grandmother rubbed cow dung over his umbilical cord, a traditional practice, for it to dry up quickly. These are ...Missing: herbal pastes
  17. [17]
    Maternal and Neonatal Tetanus Elimination - Dove Medical Press
    Nov 23, 2021 · ... cow dung, herbs, oils, spices, etc. on the cord. Clean birth practices have been shown to decrease the incidence of neonatal tetanus by 55–99%.Missing: pastes | Show results with:pastes<|control11|><|separator|>
  18. [18]
    Newborn Tetanus - an overview | ScienceDirect Topics
    Neonatal tetanus is a generalized form of the disease that occurs only in infants born to inadequately immunized mothers.
  19. [19]
    Tetanus (Lockjaw) Symptoms, Causes & Treatment - Cleveland Clinic
    May 14, 2025 · The main risk factors for neonatal tetanus include: An unvaccinated or partially vaccinated mother; Umbilical cord wound contamination from ...<|separator|>
  20. [20]
    Global Impact of Tetanus - CDC
    May 15, 2024 · Neonatal tetanus happens when newborns show symptoms within the first 28 days of life. Pregnant women and newborns can get infected with tetanus ...
  21. [21]
    Tetanus - UpToDate
    Sep 29, 2025 · Improving hygiene during home births in resource-limited settings is also likely to play an important role in preventing neonatal tetanus.
  22. [22]
    Tetanus: Pathophysiology, Treatment, and the Possibility of Using ...
    Jan 8, 2013 · The muscular rigidity and spasms of tetanus are caused by tetanus toxin (tetanospasmin), which is produced by Clostridium tetani, an anaerobic ...
  23. [23]
    Tetanospasmin - an overview | ScienceDirect Topics
    Once inside the nervous system, tetanospasmin blocks the release of inhibitory neurotransmitters, such as gamma-aminobutyric acid (GABA) and glycine, by ...Introduction to Tetanospasmin... · Molecular Mechanism of...
  24. [24]
    Neonatal Tetanus Case Series: A Tale of Survival and Tragedy at St ...
    Jul 26, 2024 · Risk factors for maternal and newborn tetanus (MNT) include deliveries on contaminated surfaces or by individuals with unclean hands. Therefore, ...
  25. [25]
    Neonatal tetanus - :: Pediatric Emergency Medicine Journal
    Jun 9, 2021 · Contamination of the umbilical cord stump is the main cause. The typical, early manifestations are weakness and lack of ability to suck ...
  26. [26]
    Tetanus: Recognition and Management - PMC - PubMed Central
    Jul 20, 2025 · C. tetani produces a potent neurotoxin. Tetanus neuro-toxin (TeNT) is transported retrogradely to the central nervous system (CNS), where it ...
  27. [27]
    Tetanus - an overview | ScienceDirect Topics
    Complications include laryngospasm, fractures, hypertension, nosocomial infections, and death. Treatment is primarily supportive, although metronidazole or ...
  28. [28]
    [PDF] Tetanus Reporting and Investigation Guideline
    Complications of generalized tetanus include fractures, difficulty breathing (due to spasms of the respiratory muscles), hypertension, abnormal heart ...
  29. [29]
    Tetanus | Journal of Neurology, Neurosurgery & Psychiatry
    Respiratory failure is the commonest direct cause of death from tetanus ... The common complications in tetanus, such as nosocomial infection, bed sores ...
  30. [30]
    Tetanus Clinical Presentation: History, Physical Examination ...
    Feb 5, 2025 · Common first signs of tetanus are headache and muscular stiffness in the jaw (ie, lockjaw), followed by neck stiffness, difficulty swallowing, ...
  31. [31]
    Long-term outcome in survivors of neonatal tetanus ... - PubMed
    Sep 25, 2017 · No significant reductions in growth indices or neurodevelopmental scores were shown in survivors of neonatal tetanus compared to controls ...Missing: delays | Show results with:delays
  32. [32]
    Prognosis of neonatal tetanus in the modern management era
    Without medical treatment mortality rates are very high (some reports are of 99% fatality). As tetanus evolves over days in a characteristic manner, the ...Missing: ICU | Show results with:ICU
  33. [33]
    [PDF] Neonatal Tetanus - World Health Organization (WHO)
    Sep 5, 2018 · Autonomic nervous system dysfunction. (hypertension, abnormal pulse) and spasm of respiratory muscles and larynx can lead to respiratory failure ...
  34. [34]
    A ten-year review of neonatal tetanus cases managed at a tertiary ...
    Diagnosis of tetanus was made clinically according to the WHO diagnostic criteria [24] with all 3 of the following: A child who has been crying and feeding ...
  35. [35]
    Newborn Tetanus - an overview | ScienceDirect Topics
    Tetanus is caused by the toxin-producing bacteria Clostridium tetani and, in newborns, is usually due to infection of the umbilical cord stump. Highly effective ...
  36. [36]
    [PDF] New Jersey Department of Health - Tetanus
    Attempts to culture C. tetani are associated with poor yield, and a negative culture does not rule out disease. A protective serum antitoxin concentration ...
  37. [37]
    Antitetanus toxoid antibodies in mothers and neonates
    Aug 2, 2023 · Antitoxin antibody titres of 0.1–0.15 IU/mL are considered protective but neonates born to mothers with suboptimal levels are at risk of death ...
  38. [38]
    Tetanus Workup: Approach Considerations, Laboratory Studies ...
    Feb 5, 2025 · No specific laboratory tests exist for determining the diagnosis of tetanus. The diagnosis is clinically based on the presence of trismus, dysphagia, ...Approach Considerations · Laboratory Studies · Spatula Test
  39. [39]
    [Electromyography as a Diagnostic Aid in Tetanus] - PubMed
    We consider electromyography a very useful and reliable tool either to confirm or rule out the diagnosis of tetanus.
  40. [40]
    Intensive Care Management of Severe Tetanus - PubMed Central
    The bacteria produce a potent metalloprotease toxin called tetanospasmin, which is responsible for the disease. The gene for tetanospasmin production is located ...<|control11|><|separator|>
  41. [41]
    Pharmacological management of tetanus: an evidence-based review
    Mar 26, 2014 · Benzodiazepines. Benzodiazepines are the standard therapy for controlling muscle spasms in tetanus and have gained popularity over other agents ...
  42. [42]
    Tetanus - Infectious Diseases - Merck Manual Professional Edition
    Pathophysiology of Tetanus​​ Manifestations of tetanus are caused by an exotoxin (tetanospasmin) produced when bacteria lyse. The toxin enters peripheral nerve ...Missing: immature | Show results with:immature
  43. [43]
    Tetanus Treatment & Management - Medscape Reference
    Feb 5, 2025 · Passive immunization with human tetanus immune globulin (TIG) shortens the course of tetanus and may lessen its severity.
  44. [44]
    Eradication of tetanus - PMC - PubMed Central - NIH
    In the case of neonatal tetanus, the entry site is the umbilical stump and traditional birth practices such as cutting the cord with grass or applying cow dung ...
  45. [45]
    Tetanus Disease, Treatment, Management | Pediatrics In Review
    Aug 1, 2018 · Autonomic instability can be treated with clonidine, β-blockers, and morphine. Other components of tetanus treatment include administration of ...
  46. [46]
    Neonatal Tetanus in Vietnam: Comprehensive Intensive Care ... - NIH
    The latter allowed rapid detection of autonomic instability which was treated with magnesium sulphate. This is the first report of its use in neonatal tetanus.
  47. [47]
    Clinical Care of Tetanus - CDC
    Jun 10, 2025 · Healthcare providers should use sedation and muscle relaxant drugs as indicated to control muscle spasms. Patients may require agents to control ...Missing: neonatal | Show results with:neonatal
  48. [48]
  49. [49]
    Tetanus - One Health Trust - About
    Also administer Human Tetanus Immunoglobulin (IM): neonates 500 IU, children 2000 IU, adults 3000-6000 IU. · Wound care and debridement/umblical cord care is ...Missing: immune globulin
  50. [50]
    Maternal and neonatal tetanus - PMC - PubMed Central
    Aug 19, 2014 · In maternal tetanus, infection occurs after abortion, miscarriages, or unhygienic delivery practices, whereas neonatal tetanus infection usually ...Missing: dung pastes
  51. [51]
    Neonatal Tetanus Case Series: A Tale of Survival and Tragedy at St ...
    Jul 26, 2024 · Untreated neonatal tetanus has a near 100% fatality rate, which can be reduced to 10–20% with intensive care. The majority of tetanus cases are ...
  52. [52]
    Prognostic factors in neonatal tetanus - Wiley Online Library
    Oct 9, 2008 · Mortality was significantly higher for an incubation period of 6 days or less: it was 71.2% (52/73), while it was 46.8% (44/94) among neonates ...Introduction · Results · Discussion<|separator|>
  53. [53]
    [PDF] Protecting all against tetanus - World Health Organization (WHO)
    In general, shorter incubation periods are associated with more heavily contaminated wounds, more severe disease, and a worse prognosis. For neonatal tetanus, ...
  54. [54]
    Prognostic factors for mortality in neonatal tetanus - ScienceDirect.com
    Previous studies have shown that a short incubation period and low birth weight14, 15 are associated with a high mortality rate and are poor prognostic factors.
  55. [55]
    Maternal and Neonatal Tetanus Elimination (MNTE) in The WHO ...
    Vaccination will ensure that the women have high enough antibodies against tetanus toxin to pass on to unborn children during pregnancy, which will protect ...
  56. [56]
    Progress Toward Achieving and Sustaining Maternal and Neonatal ...
    Jul 18, 2024 · To protect infants from tetanus susceptibility at birth, women of reproductive age (usually 15–49 years) should be vaccinated with ≥2 doses of ...
  57. [57]
    Updated Recommendations for Use of Tetanus Toxoid, Reduced ...
    To ensure protection against maternal and neonatal tetanus, pregnant women who never have been vaccinated against tetanus should receive three vaccinations ...
  58. [58]
    Number of tetanus toxoid injections before birth and associated ...
    May 21, 2024 · Pregnant women should receive at least two doses of the tetanus vaccine, according to the dose intervals, to maintain antibody levels above the ...<|separator|>
  59. [59]
    Tetanus Vaccine Recommendations - CDC
    Sep 24, 2024 · CDC recommends women get Tdap during the early part of the 3rd trimester of every pregnancy. While Tdap also helps protect against tetanus and ...
  60. [60]
    Vaccines for women for preventing neonatal tetanus - PubMed Central
    It occurs in newborn infants born to mothers who do not have sufficient circulating antibodies to protect the infant passively, by transplacental transfer.
  61. [61]
    Uptake of protective tetanus toxoid vaccine doses and maternal ...
    Jul 18, 2024 · Vaccinating pregnant women with tetanus toxoid (TT) is crucial to prevent neonatal tetanus, reducing related deaths by 94%.
  62. [62]
    Determinants of tetanus immunization among pregnant women ...
    Mar 13, 2025 · Two or more doses of the tetanus toxoid (TT) vaccine in pregnancy afford the fetus passive immunity and reduce neonatal mortality by 96%.
  63. [63]
    Effectiveness of prenatal tetanus toxoid immunization against ...
    Immunization of pregnant women with tetanus toxoid was the single most effective intervention against neonatal tetanus independent of other interventions.
  64. [64]
    Maternal and Neonatal Tetanus - WHO | Regional Office for Africa
    Local access to clean and safe delivery practices: The application of clean delivery practices, including the use of sterilized tools to sever the umbilical ...
  65. [65]
    Neonatal tetanus associated with topical umbilical ghee
    Apr 14, 1999 · to cut the cord, 'dirty cord' (dung or ash applied to the umbilical wound), 'maternal ghee' (pre-delivery application of ghee to abdomen ...
  66. [66]
    Protective effects of topical antimicrobials against neonatal tetanus.
    Application of animal dung or ash to the umbilical wound was hazardous. Similarly, predelivery cutaneous or intravaginal exposure of mothers to ghee ...
  67. [67]
    Clean birth and postnatal care practices to reduce neonatal deaths ...
    Apr 13, 2011 · According to expert opinion, clean birth and particularly postnatal care practices are effective in reducing neonatal mortality from sepsis and tetanus.Missing: herbal | Show results with:herbal
  68. [68]
    Eliminating Maternal and Neonatal Tetanus and Promoting Clean ...
    In maternal tetanus, infection can occur after miscarriages, abortion, as well as unclean and hygienic delivery practices. Prevention is carried out through ...
  69. [69]
    Progress Toward Maternal and Neonatal Tetanus Elimination - CDC
    May 1, 2020 · Neonatal tetanus occurs during the first 28 days of life; neonatal tetanus infection occurs following cutting the umbilical cord under ...Missing: symptoms | Show results with:symptoms
  70. [70]
    Progress towards global MNT elimination
    By December 2024, 49 countries have been validated as having achieved MNT elimination: The map shows the 49 countries out of 59 countries at risk for MNTE since ...
  71. [71]
    Diphtheria tetanus toxoid and pertussis (DTP) vaccination coverage
    These data represent administrative and official Diphtheria Tetanus Toxoid and Pertussis (DTP) vaccination coverage reported annually through the WHO/UNICEF ...
  72. [72]
    Maternal and Neonatal Tetanus Elimination: Where are We Now?
    Nov 23, 2021 · WHO estimated that 787,000 neonatal deaths occurred due to neonatal tetanus in 1988 and this reduced to 25,000 in 2018 (Figure 1). The actual ...
  73. [73]
    Performance of the Neonatal Tetanus Surveillance System (NTSS ...
    May 4, 2021 · High-quality NT surveillance is a key component of the NT elimination strategy, and its data are used to identify areas or subpopulations at ...
  74. [74]
    Global epidemiology and burden of tetanus from 1990 to 2019
    Apr 20, 2023 · The incidence and death of tetanus decreased significantly from 1990 to 2019. Neonatal tetanus is serious in low and middle sociodemographic ...
  75. [75]
    Neonatal Tetanus Still Exists: A Case Report and Review of Literature
    May 31, 2024 · Umbilical stump sepsis in newborns born to unvaccinated mothers is a major risk factor for NT. The World Health Organization describes NT as ...
  76. [76]
    Risk Factors for Neonatal Tetanus --- Busoga Region, Uganda, 2002
    Apr 28, 2006 · This study identified two risk factors for NNT: unclean delivery surfaces and primigravidae mothers. Protective factors were the mother ...<|separator|>
  77. [77]
    Risk factors of neonatal tetanus in Wenzhou, China: a case-control ...
    Jul 6, 2015 · This study identified that the main risks of neonatal tetanus in cases from Wenzhou were having an untrained birth attendant, home delivery and an unsterile ...
  78. [78]
    Incidence and Risk Factors for Neonatal Tetanus in Admissions to ...
    Apr 7, 2015 · Age at admission, presence of inflamed umbilicus, prostration, number of spams per 5 minutes, NT score and presence of hypoglycaemia were all ...
  79. [79]
    a cross-national analysis in 33 sub-Saharan African countries
    Oct 31, 2023 · Sub-Saharan Africa (SSA) and South Asia account for most new cases of tetanus.3 The two regions account for 82% of all tetanus cases globally.
  80. [80]
    Global analysis of tetanus incidence and mortality in children under ...
    May 14, 2025 · Similarly, tetanus mortality among children has decreased significantly over the past 30 years, from 24.62 per 100 000 to 1.34 per 100 000, with ...
  81. [81]
    Tetanus - Our World in Data
    But by 2019, infection rates had declined in many countries, and only a few countries worldwide had infection rates of tetanus greater than 5 per 100,000 people ...
  82. [82]
    [PDF] MATERNAL AND NEONATAL TETANUS ELIMINATION - PAHO
    Pan American Health Organization. Maternal and neonatal tetanus elimination in Latin America and the Caribbean. Field Guide. Washington, D.C.: PAHO; 2024.
  83. [83]
    Guinea Celebrates Elimination Of Maternal And Neonatal Tetanus
    Aug 20, 2024 · With Guinea achieving elimination status, only 10 countries are still fighting to eliminate MNT: Afghanistan, Angola, Central African Republic, ...
  84. [84]
    Living standard and access to tetanus toxoid immunization among ...
    May 24, 2022 · The educated mothers had 47% (p-value< 0.001) higher odds of having vaccinated with TT compared to the uneducated mothers. Women who had their ...Missing: correlation literacy
  85. [85]
    Maternal immunisation towards prevention of neonatal tetanus
    Sep 29, 2025 · Access to maternal healthcare services and media exposure. Most pregnant women (45.6%) reported attending ANC between 4 and 7 times during ...Missing: correlation female literacy
  86. [86]
    Vaccination governance in protracted conflict settings: the case of ...
    Sep 12, 2024 · This study evaluates the governance of vaccination programs in northwest Syria, focusing on effectiveness, efficiency, inclusiveness, data availability, vision ...
  87. [87]
    St Kilda, the neonatal tetanus tragedy of the nineteenth century and ...
    Neonatal tetanus was the cause of death of two thirds of newborn babies on the archipelago of St Kilda in the Outer Hebrides for at least 150 years.
  88. [88]
    Neonatal Tetanus on the Westman Islands - PubMed
    Apr 8, 2011 · At the beginning of the 1800 s neonatal tetanus was a major health hazard on the Westman Islands, an archipelago immediately south of Iceland.
  89. [89]
    Tetanus: historical and palaeopathological aspects considering its ...
    The antiquity of the disease is described thanks to historical written sources, artistic references and very recent palaeogenetic data.
  90. [90]
    Battling Tetanus | Smithsonian Institution
    A vaccine to prevent tetanus – tetanus toxoid – was introduced in 1924. Tetanus toxoid is an inactivated form of the toxin; it teaches the body to recognize ...<|separator|>
  91. [91]
    History of Tetanus Vaccine
    In the mid- 1920's, vaccine researchers developed a tetanus toxoid vaccine by inactivating the tetanus toxin using both formaldehyde and heat.
  92. [92]
    Early U.S. Military Immunization Against Tetanus and Diphtheria ...
    Aug 1, 2025 · The U.S. Army had 70 tetanus cases per million soldiers in the First World War compared to only 12 cases, most not fully immunized, or 1 per ...
  93. [93]
    Early U.S. Military Immunization Against Tetanus and Diphtheria - NIH
    Aug 20, 2025 · The U.S. military problem of tetanus during World War II was largely solved by consistent toxoid immunization of the entire population. As ...
  94. [94]
    Maternal and neonatal tetanus elimination: from protecting women ...
    Administration of properly-spaced doses of TTCVs during the antenatal period can reduce the incidence of NT by up to 88%–100%, and can help to achieve MNT ...
  95. [95]
    Region of the Americas eliminates maternal and neonatal tetanus
    Sep 21, 2017 · According to data from WHO, neonatal tetanus killed about 34,000 newborn children in 2015, a 96% reduction from 1988, when an estimated 787,000 ...
  96. [96]
    Fast Facts: Global Tetanus Vaccination - CDC
    May 16, 2024 · Newborns who survive tetanus can have severe long-term neurologic, behavioral, and intellectual abnormalities. While anyone can get tetanus, the ...<|separator|>
  97. [97]
    Neonatal tetanus associated with topical umbilical ghee: Covert role ...
    Aug 10, 2025 · 1 At least 40.0%-50.0% of deaths occur in neonates especially due to unhygienic conditions during birth and social practices like smearing cow ...Missing: pastes | Show results with:pastes
  98. [98]
  99. [99]
    Determinants of potentially harmful traditional cord care practices ...
    Aug 29, 2022 · These practices often take place under unsterilized conditions; hence, they increase the risk of umbilical infection and neonatal tetanus.
  100. [100]
    Research reports The impact of traditional birth attendant training on ...
    Ross concluded that the evidence that TBA training, by itself, led to a reduction in neonatal tetanus was inconclu- sive, citing weak methodology as the main ...
  101. [101]
    Epidemiological and clinical aspects of neonatal tetanus from a ...
    All of the patients were intubated and receiving mechanical ventilation. Six (20%) of the patients died. Conclusion. It is essential to begin campaigns or ...<|control11|><|separator|>
  102. [102]
    Statement from WHO and UNICEF on the Tetanus Vaccine in Kenya
    The World Health Organization (WHO) and the United Nations Children's Fund (UNICEF) express their deep concern about the misinformation circulating in the media ...Missing: hesitancy | Show results with:hesitancy
  103. [103]
    Kenya Catholic Church tetanus vaccine fears 'unfounded' - BBC News
    Oct 13, 2014 · Kenya's government has dismissed allegations made by the country's Catholic Church that a tetanus vaccine can cause sterility in women.Missing: hesitancy | Show results with:hesitancy
  104. [104]
    Video repeats the false claim that the tetanus vaccine causes sterility
    The myth that tetanus vaccines cause sterility has circulated for three decades. Debunking messaging may explain that this disproven rumor is based on the ...Missing: neonatal hesitancy 2014
  105. [105]
    Philosophic objection to vaccination as a risk for tetanus ... - PubMed
    Among all unvaccinated cases, objection to vaccination, either religious or philosophic, was the reported reason for choosing not to vaccinate. Conclusion: The ...
  106. [106]
    Tetanus Surveillance -- United States, 1995-1997 - CDC
    Jul 3, 1998 · One case of neonatal tetanus was reported in an infant ... vaccines because their parents had religious or philosophic objections to vaccination.
  107. [107]
    Church supports UNICEF tetanus vaccination campaign
    Aug 3, 2023 · The Church of Jesus Christ of Latter-day Saints has supported UNICEF's maternal and neonatal tetanus elimination programs since 2014.
  108. [108]
    Tdap Vaccination for Pregnant Women | Whooping Cough - CDC
    Oct 31, 2024 · Tdap is very safe for pregnant women and their babies. Getting vaccinated during pregnancy won't increase risk for pregnancy complications. None ...Missing: neonatal | Show results with:neonatal
  109. [109]
    Tdap vaccination during pregnancy and risk of chorioamnionitis and ...
    Tdap vaccine exposure during pregnancy was not associated with chorioamnionitis, preterm birth, or adverse infant outcomes.
  110. [110]
    Update on Immunization and Pregnancy: Tetanus, Diphtheria, and ...
    As part of standard wound management care to prevent tetanus, a tetanus toxoid-containing vaccine is recommended in a pregnant woman if 5 years or more have ...
  111. [111]
    Tetanus Vaccine Knowledge, Beliefs, and Attitudes Among Syrian ...
    Feb 2, 2025 · In this qualitative study, we aimed to evaluate the knowledge, beliefs, and attitudes of Syrian pregnant women living in Türkiye toward tetanus vaccination.
  112. [112]
    Systematic review and meta-analysis of interventions to increase the ...
    Apr 19, 2025 · Recent data in the US indicate the problem may be worsening, with declining rates of some vaccines and increasing rates of vaccine hesitancy ...
  113. [113]
    Immunization to Prevent Maternal and Neonatal Tetanus - GiveWell
    MNT can be prevented by ensuring that all deliveries are assisted by skilled health attendants – whether at health facilities or during home delivery – who can ...
  114. [114]
    Comparison of Wealth-Related Inequality in Tetanus Vaccination ...
    Average TTCV coverage was significantly lower among countries which had not achieved MNTE relative to countries which had achieved MNTE before pregnancy (6.0% ...